Lutein mitigates cyclophosphamide induced lung and liver injury via NF-κB/MAPK dependent mechanism

• Published in: Biomedicine & pharmacotherapy 2017-08, Vol.92, p.519-527
• Main Authors: El-Kholy, Amal A, Elkablawy, Mohamed A, El-Agamy, Dina S
• Format: Article
• Language: English
• Subjects: Acute Lung Injury - chemically induced; Acute Lung Injury - metabolism; Acute Lung Injury - prevention & control; Animals; Chemical and Drug Induced Liver Injury - metabolism; Chemical and Drug Induced Liver Injury - prevention & control; Cyclophosphamide; Cyclophosphamide - toxicity; Hepatotoxicity; Internal Medicine; Lutein; Lutein - pharmacology; Lutein - therapeutic use; Male; MAPK; Medical Education; Mice; Mitogen-Activated Protein Kinases - antagonists & inhibitors; Mitogen-Activated Protein Kinases - metabolism; NF-kappa B - antagonists & inhibitors; NF-kappa B - metabolism; NF-κβ; Pulmonary injury; Random Allocation
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2017.05.103

Abstract This study targeted to test the potential protective role of lutein against lung and liver damage associated with cyclophosphamide (CP) administration. Lutein was given orally for 5 days at two different doses both before and after CP injection. Results have shown that CP administration caused marked pulmonary and hepatic injurious effects in mice. Lung damage was evident through increased lung wet/dry ratio, elevated inflammatory cells infiltration into the pulmonary tissues, increased total protein content and lactate dehydrogenase (LDH) activity in the broncho-alveolar lavage fluid. Estimation of high levels of serum transaminases, alkaline phosphatase and LDH in serum revealed hepatic injury. Histopathological examination of both organs confirmed the biochemical analysis. Elevation of oxidative stress along with depressed anti-oxidant status of lung and liver were evident in CP-intoxicated animals. Furthermore, CP induced elevation of inflammatory cytokines (NOx, TNF-α, IL-6) contaminant with activation of nuclear factor kappa-B (NF-κB) and p38 mitogen activated protein kinase (p38-MAPK). On the other side, lutein treatment successfully protected the lung and the liver as indicated by improvement of the biochemical and histopathological parameters. These results suggest that lutein can ameliorate CP-induced pulmonary and hepatic oxidative injurious effects via inhibition of reactive oxygen species (ROS)/NF-κB/MAPK pathway.